| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 31.49 | -0.71 (-2.20%) | 21.05 - 39.00 | 399.9 thousand (Below Avg) |
Market data as of 4:00PM 06/19/13. Quotes are delayed by at least 15 min.
| Open | 32.26 |
|---|---|
| Previous Close | 32.20 |
| Day's Range | 31.37 - 32.40 |
| Market Cap | 3.8B |
| Avg Volume (10 Day) | 596.7K |
| Price/Earnings (Trailing 12 Mo.) | -- |
| Earnings Per Share (Trailing 12 Mo.) | -0.5 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Pass |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Fail |
| Increased shareholder value? | Fail |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Neutral |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Fail |
| Borrows within reasonable limits? | Pass |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Fail |
| Has sufficient liquidity? | Pass |
Takeda and Seattle Genetics Highlight Post-Hoc Analysis Examining Progression-free Survival with ADCETRIS® (brentuximab vedotin) Versus Prior Therapy at the International Conference on Malignant Lymphoma
Business Wire - Wednesday 06/19/2013 9:00 AM ET
Seattle Genetics Announces Initiation of Phase 1/2 Trial of ADCETRIS® (Brentuximab Vedotin) in Combination with Bendamustine for Hodgkin Lymphoma Patients after Initial Relapse
Business Wire - Monday 06/10/2013 9:00 AM ET
Collaborations, Clinical Development Programs, FDA Approvals, New Treatments and Attractive Product Portfolios - Research Report on Medivation, Acadia, Santarus, Seattle Genetics, and PDL BioPharma
PR Newswire - Monday 06/10/2013 8:00 AM ET
Seattle Genetics Highlights ADCETRIS® (Brentuximab Vedotin) Frontline HL and MTCL Clinical Development Programs and Antibody-Drug Conjugate (ADC) Collaborator Data at ASCO Annual Meeting
Business Wire - Sunday 06/02/2013 9:00 AM ET
Seattle Genetics to Present at Upcoming Investor Conferences
Business Wire - Wednesday 05/29/2013 9:00 AM ET
| SGEN | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | 68.05% | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | 0.00 | |
| LT Debt/Equity | 0.00 | |
| Earnings Yield | -- | |
| Price/Sales | 17.76 |
| Company | Last | Change |
|---|---|---|
| Jazz Pharmaceuticals PLC | 68.28 | -1.98% |
| Medivation Inc | 46.58 | -4.45% |
| Theravance Inc | 35.25 | -1.29% |
| ARIAD Pharmaceuticals Inc | 17.22 | -3.18% |
| Incyte Corp | 20.36 | -4.90% |
Data is delayed by at least 15 min.